Trials / Completed
CompletedNCT00261287
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Tolerability of Ciclesonide (200 mcg Once Daily), Applied as a Nasal Spray for Twelve Weeks, in the Treatment of Perennial Allergic Rhinitis (PAR) in Pediatric Patients 2-5 Years of Age
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 102 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 2 Years – 5 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of ciclesonide nasal spray for long term use in relieving symptoms in perennial allergic rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ciclesonide |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2006-06-01
- Completion
- 2006-06-01
- First posted
- 2005-12-05
- Last updated
- 2016-11-30
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00261287. Inclusion in this directory is not an endorsement.